In a groundbreaking advancement poised to transform the landscape of rare disease diagnostics, researchers at the Children’s Hospital of Philadelphia (CHOP) have unveiled a pioneering RNA sequencing methodology designed to deepen our understanding of how genetic variants compromise gene function. This innovative approach, detailed in the journal Science Advances on April 15, 2026, overcomes existing limitations in rare disease diagnostics by employing targeted long-read RNA sequencing to detect pathogenic genetic variants that have so far eluded standard genomic analyses.
Traditional genetic diagnostics often rely heavily on exome and whole-genome sequencing to identify mutations responsible for rare diseases. However, such methods, while powerful, exhibit a diagnostic yield ranging only between 20% to 50%, leaving a majority of patients without concrete molecular diagnoses. This diagnostic gap emerges largely because DNA sequencing alone cannot capture the complexities of RNA transcription and processing alterations caused by certain genetic variants. To bridge this critical knowledge gap, scientists have increasingly turned towards RNA sequencing, which directly interrogates the molecules that convey genetic information into proteins, thus providing a clearer functional context.
The CHOP team, led by Dr. Yi Xing, Associate Chief Scientific Officer for Omics, Technology & Engineering, and a luminary in computational and genomic medicine, addressed these challenges by developing STRIPE—short for Sequencing Targeted RNAs Identifies Pathogenic Events. STRIPE leverages the advantages of long-read RNA sequencing technology, which differs from traditional short-read RNA sequencing by reading entire RNA molecules in one continuous stretch. This full-length sequencing capability is crucial as it preserves the context of multiple genetic variants and splicing events across the same RNA transcript, enabling a high-resolution view of the molecular consequences of genetic mutations.
Despite the immense potential of long-read RNA sequencing, its adoption in clinical diagnostics has been hindered by issues including high costs, lower throughput, and suboptimal accuracy compared to short-read methods. The STRIPE platform surmounts these obstacles by integrating targeted sequencing with a cost-effective, scalable workflow built upon CHOP’s predecessor technology, TEQUILA-seq. TEQUILA-seq was initially developed to offer a versatile and affordable means of sequencing entire RNA molecules, facilitating large-scale studies without prohibitive expense. STRIPE advances this concept further, focusing sequencing depth on bespoke panels of disease-relevant genes, enabling ultra-deep sequencing at an approximate RNA-to-data cost of $100 per sample—an affordability milestone that makes routine clinical application feasible.
The efficacy of STRIPE was rigorously evaluated using cohorts of individuals affected by congenital disorders of glycosylation (CDG) and primary mitochondrial diseases (PMD), two groups of genetically heterogeneous rare diseases extensively researched at CHOP. These diseases are characterized by complex pathogenic mechanisms and subtle RNA perturbations, making them ideal candidates to validate the diagnostic precision and mechanistic insights provided by STRIPE. Notably, the study demonstrated that STRIPE could accurately detect previously known pathogenic variants, elucidate the intricate RNA processing consequences of these mutations, and crucially, identify novel disease-causing variants in patients who had previously remained without diagnosis despite exhaustive testing.
A pivotal advantage of the STRIPE strategy is its ability to analyze RNA extracted from clinically accessible tissues such as patient blood or skin fibroblasts. This feature addresses a longstanding challenge in RNA-guided diagnostics: the difficulty in obtaining disease-relevant tissue samples from patients due to invasiveness or inaccessibility. Dr. Rebecca Ganetzky, a clinical geneticist at CHOP’s Mitochondrial Medicine Program, emphasized that STRIPE’s capacity to derive meaningful diagnostic signals from such accessible samples profoundly enhances its clinical utility, enabling physicians to interrogate RNA-level disruptions without invasive biopsies.
This innovative platform extends beyond mere diagnostic yield. By providing a detailed map of how specific genetic variants alter RNA molecules—through mechanisms such as aberrant splicing, transcript truncation, and expression imbalances—STRIPE bridges the longstanding divide between genetic findings and functional understanding. This molecular granularity equips clinicians with actionable insights into disease mechanisms, facilitating informed clinical decision-making and opening pathways towards tailored therapeutic interventions targeted at the underlying RNA dysfunction.
Collaborative efforts with specialized clinical programs, such as CHOP’s CDG Clinic directed by Dr. Andrew C. Edmondson, validated STRIPE’s diagnoses by correlating them with measurable biochemical disruptions in glycosylation pathways. This multidisciplinary integration not only verified the technology’s clinical relevance but also accelerated patient access to molecular diagnoses that had previously been unattainable by conventional methods. These achievements underscore the potential of STRIPE to conclude often-protracted diagnostic odysseys for patients afflicted with rare diseases, thereby improving their clinical management and quality of life.
The comprehensive evaluation encompassed 88 individuals, including rare disease patients and healthy controls, and unequivocally demonstrated STRIPE’s sensitivity and specificity in detecting pathogenic RNA alterations. Beyond confirming known variants, the platform revealed complex RNA consequences of mutations that had been underestimated, thereby refining the interpretation of variants of uncertain significance—a notorious obstacle in clinical genetics. Perhaps most strikingly, STRIPE yielded new molecular diagnoses in five patients previously undiagnosed after exhaustive genetic work-ups, emblematic of its transformative clinical potential.
Since its inception, STRIPE has been deployed on over 500 patients within various CHOP clinical programs, reinforcing its robustness, scalability, and readiness for integration into real-world rare disease diagnostic pipelines. This extensive application highlights the platform’s adaptability to diverse clinical contexts and its promise to catalyze advances in personalized medicine through RNA-guided precision diagnostics.
The scientific implications of STRIPE extend into the therapeutic realm. By elucidating the RNA-level disruptions caused by genetic variants, this methodology paves the way for the development of RNA-targeted therapies—ranging from antisense oligonucleotides to RNA editing strategies—that directly rectify pathogenic transcripts. This convergence of diagnostic precision and therapy holds the promise of ushering in a new era of precision medicine in rare diseases, where molecular diagnoses seamlessly inform bespoke treatment strategies.
Fundamentally, STRIPE embodies a paradigm shift in rare disease genomics, moving beyond DNA-centric views to embrace the transcriptional and post-transcriptional complexities that drive disease. As Dr. Yi Xing articulated, the platform represents “a bridge from genetic diagnosis to disease mechanism to targeted therapies,” heralding a future where full-length RNA sequencing is a cornerstone of clinical genetics.
This cutting-edge research was supported by a multitude of grants from the National Institutes of Health and institutional programs at CHOP, emphasizing the collaborative and well-funded nature of this endeavor. Moreover, the CHOP team has filed a patent application for the STRIPE technology, signifying its potential for widespread clinical deployment and commercial translation.
In summary, the development of STRIPE advances a vital frontier in genetics by illuminating the elusive impact of variants at the RNA level with unprecedented clarity, accuracy, and clinical applicability. This innovation marks a critical step toward resolving the diagnostic challenges faced by many rare disease patients worldwide and underscores the transformative power of integrating advanced sequencing technologies into precision medicine frameworks.
Subject of Research: People
Article Title: Targeted long-read RNA sequencing for rare disease diagnosis and variant interpretation
News Publication Date: 15-Apr-2026
Web References: http://dx.doi.org/10.1126/sciadv.ady9895
References: Wang et al, “Targeted long-read RNA sequencing for rare disease diagnosis and variant interpretation.” Sci Adv. Online April 15, 2026. DOI: 10.1126/sciadv.ady9895.
Keywords
Genetics, Pediatrics, RNA sequencing, Long-read sequencing, Rare disease diagnostics, Congenital disorders of glycosylation, Primary mitochondrial diseases, Molecular diagnosis, Precision medicine, RNA-level variant interpretation, CHOP, STRIPE technology
Tags: Children’s Hospital of Philadelphia researchcomputational genomics in medicinefunctional genomics in rare diseasegenetic mutation identificationgenetic variant detectionimproving diagnostic yield for rare diseasesinnovative RNA sequencing platformovercoming DNA sequencing limitationsrare disease diagnosticsRNA transcription and processing analysisRNA-based molecular diagnosistargeted long-read RNA sequencing
